Journal
DRUG DELIVERY
Volume 23, Issue 8, Pages 2827-2837Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10717544.2015.1105323
Keywords
Cytotoxicity; lactone-carboxylate; lung cancer cells; PLGA nanoparticles; topotecan
Categories
Funding
- Indian Council of Medical Research, Government of India
Ask authors/readers for more resources
Topotecan (TPT) is indicated against a variety of solid tumors, but has restricted clinical use owing to associated pharmaceutical caveats. This study is focused at formulating a successful TPT PLGA nanosystem which ameliorates the rapid conversion of active lactone form of drug to its inactive carboxylate form and consequently improvises its efficacy. TPT PLGA nanoparticles were formulated by a double emulsion-solvent evaporation technique with sequential optimization to obtain desired particle size, PDI, zeta potential, and entrapment efficiency. Stability of TPT was ensured by maintaining an acidic pH in the drug-containing phase and the system was evaluated for in vitro-in vivo performance including cytotoxic potency. The optimized nanosystem had a particle size of 187.33 +/- 7.50 nm, a PDI of 0.179 +/- 0.05, and an entrapment efficiency of 56 +/- 1.2%. Low pH in the interior of nanoparticles stabilized the drug to remain in its active lactone form and revealed a biphasic release pattern till 15 d. Additionally, an in vitro cytotoxicity testing as well as in vivo antitumor efficacy demonstrated a significant potential of higher proliferation inhibition as compared with neat drug (TPT). Thus, the investigation summarized an innovative simple tool for developing stable TPT NPs for effective delivery for treating solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available